WDH: Evotec forges new drug alliance with Eli Lilly
Scientists at work with a microscope and pipette (symbolic image). © Catalin Rusnac / iStock / Getty Images Plus / Getty Images
(Day of the week changed: Tuesday rpt Tuesday)
HAMBURG (dpa-AFX) – The drug researcher Evotec (Evotec share)
The partner Eli Lilly is entitled to later select up to five programs from this cooperation in order to then assume responsibility for further development, clinical tests and marketing. In addition to an undisclosed upfront payment per selected program, Evotec is also eligible for up to $180 million (dollar exchange rate) of success-based milestone payments. In addition, in the event of a drug being approved, there should be staggered participation in the net sales./tav/stk/jha/
Subscribe to more news for free
ARIVA.DE publishes analyses, columns and news from various sources in this section. ARIVA.DE AG is not responsible for content that has been posted by third parties in the “News” area of this website and does not adopt it as its own. This content can be identified in particular by a corresponding “from” label below the article heading and/or by the link “To read the full article, please click here.”; The named third party is solely responsible for this content.
Other users were also interested in this article: